awmsg logo



trametinib (Mekinist®)


Reference No. 1011

Publication date:
29/01/2015


Appraisal information

trametinib (Mekinist®) 0.5 mg film-coated tablet
trametinib (Mekinist®) 1.0 mg film-coated tablet
trametinib (Mekinist®) 2.0 mg film-coated tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, trametinib (Mekinist®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Statement of Advice (SOA)
Download